-
2023-506620-87-00
11
2024-01-25
Advanced Breast Cancer in older patients
-
2022-502273-42-00
5
2023-11-08
Glaucoma
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2022-502160-20-00
5
2023-10-02
Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2022-501899-26-00
5
2023-09-01
Asthma
-
2024-520084-14-00
9
2023-05-26
Adopt immunotherapy in adult patients undergoing hematopoietic stem ce
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2023-507778-42-00
4
2023-03-08
Non-Small Cell Lung Cancer II, III
-
2022-502328-35-00
4
2023-01-30
Alpha (α)-thalassemia
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2024-517308-13-00
6
2025-12-10
Gram-negative bacteraemia
-
2024-516051-40-00
4
2025-06-10
Small Cell Lung Cancer (SCLC)
-
2024-515907-20-00
9
2025-05-23
Primary biliary cholangitis (PBC)
-
2024-513968-25-00
5
2025-04-28
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2022-501483-18-00
10
2025-03-28
Advanced Non-Small Cell Lung Cancer
-
2024-514133-38-00
5
2025-03-19
Ocular Myasthenia Gravis
-
2024-515255-38-00
4
2025-03-12
SEPSIS
-
2023-508055-40-00
6
2025-02-18
Obesity